Literature DB >> 2061122

Dose distribution following selective internal radiation therapy.

R A Fox1, P F Klemp, G Egan, L L Mina, M A Burton, B N Gray.   

Abstract

Selective Internal Radiation Therapy is the intrahepatic arterial injection of microspheres labelled with 90Y. The microspheres lodge in the precapillary circulation of tumor resulting in internal radiation therapy. The activity of the 90Y injected is managed by successive administrations of labelled microspheres and after each injection probing the liver with a calibrated beta probe to assess the dose to the superficial layers of normal tissue. Predicted doses of 75 Gy have been delivered without subsequent evidence of radiation damage to normal cells. This contrasts with the complications resulting from doses in excess of 30 Gy delivered from external beam radiotherapy. Detailed analysis of microsphere distribution in a cubic centimeter of normal liver and the calculation of dose to a 3-dimensional fine grid has shown that the radiation distribution created by the finite size and distribution of the microspheres results in an highly heterogeneous dose pattern. It has been shown that a third of normal liver will receive less than 33.7% of the dose predicted by assuming an homogeneous distribution of 90Y.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2061122     DOI: 10.1016/0360-3016(91)90797-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  Biliary complications associated with selective internal radiation (SIR) therapy for unresectable liver malignancies.

Authors:  Simon S M Ng; Simon C H Yu; Paul B S Lai; W Y Lau
Journal:  Dig Dis Sci       Date:  2008-03-05       Impact factor: 3.199

2.  Radioembolization of yttrium-90 microspheres for hepatic malignancy.

Authors:  Ravi Murthy; Paresh Kamat; Rodolfo Nuñez; Riad Salem
Journal:  Semin Intervent Radiol       Date:  2008-03       Impact factor: 1.513

3.  Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.

Authors:  Munveer Singh Bhangoo; Diraj R Karnani; Paul N Hein; Huan Giap; Harry Knowles; Chris Issa; Steve Steuterman; Paul Pockros; Catherine Frenette
Journal:  J Gastrointest Oncol       Date:  2015-10

Review 4.  The role of SPECT/CT in radioembolization of liver tumours.

Authors:  Hojjat Ahmadzadehfar; Heying Duan; Alexander R Haug; Stephan Walrand; Martha Hoffmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-18       Impact factor: 9.236

5.  Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours.

Authors:  S Ho; W Y Lau; T W Leung; M Chan; Y K Ngar; P J Johnson; A K Li
Journal:  Eur J Nucl Med       Date:  1996-08

6.  TCP post-radioembolization and TCP post-EBRT in HCC are similar and can be predicted using the in vitro radiosensitivity.

Authors:  Philippe d'Abadie; Stephan Walrand; Michel Hesse; Ivan Borbath; Renaud Lhommel; François Jamar
Journal:  EJNMMI Res       Date:  2022-07-08       Impact factor: 3.434

7.  Trans-arterial hepatic radioembolisation of yttrium-90 microspheres.

Authors:  R Murthy; A Habbu; R Salem
Journal:  Biomed Imaging Interv J       Date:  2006-07-01

8.  Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.

Authors:  Kelvin S H Loke; Ajit K Padhy; David C E Ng; Anthony S W Goh; Chaitanya Divgi
Journal:  World J Nucl Med       Date:  2011-07

9.  Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio.

Authors:  Seza A Gulec; Geraldine Mesoloras; William A Dezarn; Patrick McNeillie; Andrew S Kennedy
Journal:  J Transl Med       Date:  2007-03-14       Impact factor: 5.531

10.  Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study.

Authors:  W Y Lau; W T Leung; S Ho; N W Leung; M Chan; J Lin; C Metreweli; P Johnson; A K Li
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.